Aspirin suppresses the acquisition of chemoresistance in breast cancer by disrupting an NFκB-IL6 signaling axis responsible for the generation of cancer stem cells

Cancer Research

Volumn 76, Issue 7, 2016, Pages 2000-2012

  Saha, Shilpi ^a   Mukherjee, Shravanti ^a   Khan, Poulami ^a   Kajal, Kirti ^a   Mazumdar, Minakshi ^a   Manna, Argha ^a   Mukherjee, Sanhita ^b   De, Sunanda ^c   Jana, Debarshi ^c   Sarkar, Diptendra K ^c   Das, Tanya ^a  

^a BOSE INSTITUTE   (India)

^b BANKURA SAMMILANI MEDICAL COLLEGE   (India)

^c Seth Sukhlal Karnani Memorial Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS POTENTIAL; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; BREAST NEOPLASMS; COHORT ANALYSIS; CONFOCAL MICROSCOPY; DRUG EFFECTS; FEMALE; GENETIC TRANSFECTION; METABOLISM; PROSPECTIVE STUDY; TUMOR CELL LINE;

ASPIRIN; BREAST NEOPLASMS; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; HUMANS; INTERLEUKIN-6; MICROSCOPY, CONFOCAL; NEOPLASTIC STEM CELLS; NF-KAPPA B; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TRANSFECTION;

EID: 84963718904     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1360     Document Type: Article

References (49)

1. McMasters KM, Hunt KK. Neoadjuvent chemotherapy, locally advanced breast cancer, and quality of life. J Clin Onc 1999;17:441-4.
2. Koga KH, Moriguchi SM, Uemura G, Rodrigues JR, Pessoa EC, Matthes AGZ, et al. Monitoring the responsetoneoadjuvantchemotherapyinbreast cancer; 2013. Available from: http://dx.doi.org/10.5772/53123.
3. Montagna E, Bagnardi V, Rotmensz N, Rodriguez J, Veronesi P, Luini A, et al. Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. Br J Cancer 2008;98:1745-52.
4. Yadav BS, Sharma SC, Singh R, Singh G. Patterns of relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. J Cancer Res Ther 2007;3:75-80.
5. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
6. Yin B, Ma ZY, Zhou ZW, Gao WC, Du ZG, Zhao ZH, et al. The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triplenegative breast cancers in an orthotopic mouse model. Oncogene 2015;34:761-70.
7. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-9.
8. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009;15:4234-41.
9. Bhola NE, Balko JM, Dugger CT. TGF-β enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 2013;123:1348-58.
10. Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, et al. Shortterm single treatment ofchemotherapy results in the enrichment ofovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer 2013;12:24.
11. Williams KE, Bundred NJ, Landberg G, Clarke RB, Farnie G. Focal adhesion kinase and wnt signalling regulates human ductal carcinoma in situ stem cell activity and response to radiotherapy. Stem Cells 2015;33:327-41.
12. Cole SW. Chronic inflammation and breast cancer recurrence. JClin Oncol 2009;27:3418-9.
13. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009;1:a000141.
14. Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res 2011;17:6125-9.
15. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL-6 secretion. Proc Natl Acad Sci U S A 2011;108:1397-1402.
16. Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 2012;30:3468-77.
17. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13:518-27.
18. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010;28:1467-72.
19. Beahrs OH, Henson DE, Hutter RVP, editors. Handbook for staging of cancer. From the manual for staging on cancer. 4th ed. Philadelphia, PA: J. B. Lippincott; 1993.
20. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012;366:2438-41.
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
22. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-8.
23. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008;10:R67.
24. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 2006;12:537-44.
25. Lebret SC, Newgreen DF, Thompson EW, Ackland ML. Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res 2007;9:R19.
26. Saha S, Mukherjee S, Mazumdar M, Manna A, Khan P, Adhikary A, et al. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin. Transl Res 2015;165:558-577.
27. O'Neil MJ. The Merck index - An encyclopedia of chemicals, drugs, and biologicals. Whitehouse Station, NJ: Merck and Co., Inc.; 2006.
28. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17:1253-70.
29. Mukherjee S, Mazumdar M, Chakraborty S, Manna A, Saha S, Khan P, et al. Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/β-catenin negative feedback loop. Stem Cell Res Ther 2014;5:116.
30. Hossain DMS, Panda AK, Manna A, Mohanty S, Bhattacharjee P, Bhattacharyya S, et al. FoxP3 acts as a cotranscription factor with STAT3 in tumorinduced regulatory T cells. Immunity 2013;39:1057-69.
31. Mohanty S, Saha S, Hossain D Md S, Adhikary A, Mukherjee S, Manna A, et al. ROS-PIASc cross talk channelizes ATM signaling from resistance to apoptosis during chemosensitization of resistant tumors. Cell Death and Dis 2014;5:e1021.
32. Adhikary A, Chakraborty S, Mazumdar M, Ghosh S, Mukherjee S, Manna A, et al. Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: dual role of scaffold/matrix attachment region-binding protein 1 (SMAR1) in breast cancer cells. J Biol Chem 2014;289:25431-44.
33. Chakraborty S, Mazumdar S, Mukherjee S, Bhattacharjee P, Adhikary A, Manna A, et al. Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells. FEBS Lett 2014;588:549-59.
34. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010;288:99-106.
35. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014;32:3483-9.
36. Schrör K. Clinical applications of aspirin, in acetylsalicylic acid. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2008.
37. Maity G, De A, Das A, Banerjee S, Sarkar S, Banerjee SK. Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. Lab Invest 2015;95:702-17.
38. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29:4741-51.
39. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. Let-7 regulates selfrenewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-23.
40. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, et al. Poised chromatin at the ZEB1 promoter enables cell plasticity and enhances tumorigenicity. Cell 2013;154:61-74.
41. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011;146:633-44.
42. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65.
43. Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009;9:155.
44. Papi A, Guarnieri T, Storci G, Santini D, Ceccarelli C, Taffurelli M, et al. Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ 2012;19:1208-19.
45. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nat Commun 2011;2:162.
46. Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther 2014;7:1015-23.
47. Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 2012;47:570-84.
48. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591-601.
49. Barron TI, Flahavan EM, Sharp L, Bennett K, Visvanathan K. Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study. Cancer Res 2014;74:4065-77.